Neoantigen Peptide Vaccine

Phase 1Vaccine

TThe First Affiliated Hospital of Nanchang University

Neoantigen Peptide Vaccine is one of 52 biologic programs targeting Anatomic Stage III Breast Cancer AJCC v8. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anatomic Stage III Breast Cancer AJCC V8Recruiting

Anatomic Stage IV Breast Cancer AJCC V8Recruiting

Advanced Malignant Solid TumorsRecruiting

Anatomic Stage III Breast Cancer AJCC V8Preclinical

Recruiting

Anatomic Stage IV Breast Cancer AJCC V8Phase 1

Recruiting

Advanced Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

35 competitors in Advanced Malignant Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Gemzar

Johnson & Johnson

Phase 2

2 3

Eloxatin

Teva

Phase 2

2 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 6

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 7

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

2 8

QLS31905

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Anatomic Stage III Breast Cancer AJCC V8

NCT05269381

Q4 2028

Phase 1Recruiting

Anatomic Stage IV Breast Cancer AJCC V8

NCT05098210

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Terminated·WWashington University School of Medicine·Phase 1·NCT03956056·12 enrolled

Advanced Malignant Solid Tumors1 trial

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Recruiting·TThe First Affiliated Hospital of Nanchang University·N/A·NCT05749627·20 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Recruiting·MMayo Clinic·Preclinical·NCT05269381·138 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, Pre-Treated Nonsmall Cell Lung Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT05098210·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Neoantigen Peptide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoantigen Peptide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoantigen Peptide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Nanchang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital of Nanchang University

Neoantigen Peptide Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Pancreatic Cancer1 trial

Advanced Malignant Solid Tumors1 trial

Anatomic Stage III Breast Cancer AJCC v81 trial

Anatomic Stage IV Breast Cancer AJCC v81 trial

References

Drug Info

Quick Facts

Related News